{
  "id": "56c02bc3ef6e394741000018",
  "type": "yesno",
  "question": "Is vemurafenib effective for hairy-cell leukemia?",
  "ideal_answer": "Yes, vemurafenib is highly effective in patients with relapsed or refractory hairy-cell leukemia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25480661",
    "http://www.ncbi.nlm.nih.gov/pubmed/25815361",
    "http://www.ncbi.nlm.nih.gov/pubmed/25148599",
    "http://www.ncbi.nlm.nih.gov/pubmed/26352686",
    "http://www.ncbi.nlm.nih.gov/pubmed/24137951",
    "http://www.ncbi.nlm.nih.gov/pubmed/25774734"
  ],
  "snippets": [
    {
      "text": "CONCLUSIONS: A short oral course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26352686",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our results strongly support and inform the clinical use of BRAF and MEK inhibitors in HCL.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25480661",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The therapeutic approach of vemurafenib in treatment-refractory hairy cell leukemia is promising and offers an additional treatment option. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25774734",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25815361",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Recent identification of the recurrent V600E BRAF mutation in a majority of HCL patients has led some teams to evaluate the clinical potential of vemurafenib, a BRAF V600 specific inhibitor in a limited number of refractory HCL patients. Recently, we published the case of an HCL patient successfully treated with a low dose of vemurafenib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25815361",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We present here the successful retreatment of this patient with a second line of vemurafenib. Our data suggest for the first time that vemurafenib at the dose of 240 mg once a day could be sufficient to maintain a complete hematological remission after an initial induction treatment with low-dose vemurafenib (2 \u00d7 240 mg) daily without inducing major toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25815361",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The discovery of the BRAF mutation has created a therapeutic target exploited by oral inhibitors like vemurafenib and dabrafenib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25148599",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "[Successful use of vemurafenib in a patient with resistant hairy cell leukemia].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137951",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The frequent persistence of phosphorylated ERK-positive leukemic cells in bone marrow at the end of treatment suggests bypass reactivation of MEK and ERK as a resistance mechanism.CONCLUSIONS: A short oral course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26352686",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A short oral course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26352686",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A short oral course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26352686",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The therapeutic approach of vemurafenib in treatment-refractory hairy cell leukemia is promising and offers an additional treatment option.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25774734",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007943",
    "http://www.disease-ontology.org/api/metadata/DOID:285"
  ],
  "exact_answer": "Yes"
}